TOPPAN establishes US subsidiary in Houston to scale personalized cancer medicine

JAPAN—TOPPAN Holdings Inc. has established a new U.S. subsidiary, TOPPAN Global Medical Healthcare Inc., in Houston, Texas, marking a significant step in its push to expand personalized cancer medicine and drug discovery support on a global scale.

The company has established its base at the TMC3 Collaborative Building in Helix Park, a commercial life sciences and innovation hub situated within the Texas Medical Center (TMC)—one of the world’s largest medical complexes.

This strategic location gives TOPPAN direct access to TMC’s extensive network of cancer research institutions, clinical facilities, and patient populations, positioning the company at the heart of medical innovation in the United States.

In modern cancer treatment, demand for personalized medicine is growing rapidly around the world.

Unlike conventional treatment approaches, personalized medicine identifies the most effective therapies and drugs for each individual patient based on their unique biology.

TOPPAN Holdings aims to accelerate research and real-world implementation in this space by leveraging its proprietary invivoid™ three-dimensional cell culture technology, which enables scientists to grow and test patient-derived cells in a lab environment that closely mimics the human body.

In July 2025, TOPPAN Holdings entered into a strategic alliance with The University of Texas MD Anderson Cancer Center to co-develop clinical tools that evaluate treatment effectiveness using patient-derived samples.

The University of Texas MD Anderson Cancer Centre is one of the world’s leading institutions for cancer research and treatment.

The Houston subsidiary will now serve as the strategic headquarters, overseeing and expanding collaborations with medical institutions and pharmaceutical companies across the United States.

Three key focus areas

TOPPAN Global Medical Healthcare will concentrate its efforts across three core areas.

First, the company will accelerate clinical validation by deepening joint research with UT MD Anderson to fast-track clinical studies across multiple cancer types.

As part of this initiative, the company will aim to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certification.

This certification is a crucial step towards establishing its laboratory services as clinically reputable within the U.S. healthcare system.

Second, TOPPAN will expand its drug discovery support services by offering major U.S. pharmaceutical companies an efficient drug screening environment powered by invivoid™ technology.

This is expected to help speed up and improve the development of new cancer drugs, a process that is traditionally costly and time-consuming.

Third, the company will establish a global network by leveraging Houston’s standing as a hub of medical innovation.

Through this network, TOPPAN aims to incorporate cutting-edge scientific knowledge, attract top-tier talent, and build connections with leading research institutions to strengthen its international business development.

A long-term commitment to global healthcare

Through TOPPAN Global Medical Healthcare, TOPPAN Holdings intends to build a strong track record of clinical success in the United States — the world’s largest healthcare market.

The company has identified the medical and healthcare field as a core pillar of its long-term growth strategy and plans to continue expanding its presence aggressively on a global scale, with the ultimate goal of ensuring that every cancer patient receives the most effective treatment available to them.